Trial Filter
BETAAn intelligent search tool for clinical trials
Official Title
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Phase
Phase 4
Sponsor
Janssen Research & Development, LLC
Enrollment
295
Timeline
Mar 2022 → Oct 2037
About This Study
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Eligibility Criteria
Inclusion Criteria
- 1Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- 2Participants who have provided informed consent for this study
Locations
50 sites participating in this study
Emory University
Atlanta, Georgia 30322
Mayo Clinic Cancer Center-Scottsdale
Phoenix, Arizona 85054
City of Hope
Duarte, California 91010
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →